Francisco Beraldi-Magalhaes

Prof. Francisco Beraldi-Magalhaes

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
MFMarcia Danielle Ferreira
Marcia Danielle Ferreira
CNCynthia Pessoa das Neves
Cynthia Pessoa das Neves
ASAlexandra Brito de Souza
Alexandra Brito de Souza
FBFrancisco Beraldi-Magalhaes
Francisco Beraldi-Magalhaes
GMGiovanni Battista Migliori
Giovanni Battista Migliori
MCMarcelo Cordeiro-Santos
Marcelo Cordeiro-Santos
Objective: To identify factors predictive of mortality in patients admitted to the ICU with tuberculosis (TB)/HIV coinfection in the Manaus, Amazon Region. Methods: This was a retrospective cohort study of TB/HIV coinfected patients over 18 years of age who were admitted to an ICU in the city of Manaus, Brazil, between January of 2011 and December of 2014. Sociodemographic, clinical, and laboratory variables were assessed. To identify factors predictive of mortality, we employed a Cox proportional hazards model. Results: During the study period, 120 patients with TB/HIV coinfection were admitted to the ICU. The mean age was 37.0 ± 11.7 years. Of the 120 patients evaluated, 94 (78.3%) died and 62 (66.0%) of those deaths having occurred within the first week after admission. Data on invasive mechanical ventilation (IMV) and ARDS were available for 86 and 67 patients, respectively Of those 86, 75 (87.2%) underwent IMV, and, of those 67, 48 (71.6%) presented with ARDS. The factors found to be independently associated with mortality were IMV (p = 0.002), hypoalbuminemia (p = 0.013), and CD4 count < 200 cells/mm3 (p = 0.002). Conclusions: A high early mortality rate was observed among TB/HIV coinfected ICU patients. The factors predictive of mortality in this population were IMV, hypoalbuminemia, and severe immunosuppression.

1 March 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SOSimoni Pimenta de Oliveira
Simoni Pimenta de Oliveira
JSJuliana Taques Pessoa da Silveira
Juliana Taques Pessoa da Silveira
FBFrancisco Beraldi-Magalhaes
Francisco Beraldi-Magalhaes
RORosana Rosseto de de Oliveira
Rosana Rosseto de de Oliveira
LALuciano de Andrade
Luciano de Andrade
RCRosilene Cardoso
Rosilene Cardoso
To know the profile of adults who died by tuberculosis as the main cause, the time interval between the diagnosis and death, associated comorbidities and vulnerabilities. Observational study of secondary data regarding deaths by tuberculosis that occurred in the State of Paraná, Brazil, from 2008 to 2015. A linkage between the databases of mortality and tuberculosis notification system was conducted for data enrichment. Frequency tables, Exact Fisher test and Z test have identified statistical associations. Linkage points out 12.1% (115/944) of under-reporting in the 944 deaths identified. Early deaths accounted for 74.6% (705/944). The male sex (75.8%) was associated with the early death group. Almost half of the deaths reported in notification system (414/829) had one or more vulnerabilities. Early death were associated with respiratory system diseases and symptoms (p=0.0001) and mental and behavioral disorders (p=0.0001). High number of early deaths due TB indicate the need to seek out the respiratory symptomatic and use faster diagnostic methods. Strategies for treatment adherence, adequate monitoring of comorbidities and multisectorial support may prevent early and late death. The presence of vulnerabilities indicates that efforts beyond the health sector are needed in order to eliminate tuberculosis as public health problem.

18 February 2020 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
MFMariana Millan Fachi
Mariana Millan Fachi
RVRaquel Oliveira Vilhena
Raquel Oliveira Vilhena
BBBeatriz Böger
Beatriz Böger
EDEric Luiz Domingos
Eric Luiz Domingos
JSJosiane Marlei Müller Fernandes dos Santos
Josiane Marlei Müller Fernandes dos Santos
RPRoberto Pontarolo
Roberto Pontarolo

1 June 2022 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PIPriscila Imazu
Priscila Imazu
JSJosiane M Santos
Josiane M Santos
FBFrancisco Beraldi-Magalhaes
Francisco Beraldi-Magalhaes
FFFernando Fernandez-Llimos
Fernando Fernandez-Llimos
FTFernanda Tonin
Fernanda Tonin
RPRoberto Pontarolo
Roberto Pontarolo
Objectives: To evaluate and update the evidence on the comparative efficacy and safety of antimicrobial drugs regimens for treating pulmonary drug-susceptible tuberculosis (DS-TB). Methods: A systematic review was performed with searches in PubMed and Scopus (PROSPERO-CRD42019141463). We included randomised controlled trials comparing the effect of any antimicrobial regimen lasting at least 2 weeks. The outcomes of interest were culture conversion and incidence of adverse events. Bayesian network meta-analyses and surface under the cumulative ranking curve (SUCRA) analyses were performed. Results were reported as odds ratio with 95% credibility intervals. Key findings: Fifteen studies were included the meta-analysis (n = 7560 patients). No regimen was statistically more effective than the WHO standard approach (rifampicin, isoniazid, ethambutol, and pyrazinamide). The use of rifapentine 450 mg instead of rifampicin in the standard regimen demonstrated to be statistically safer than all other options for serious adverse events (e.g. hepatotoxicity, arthralgia) (OR ranging from 0.0 [Crl 0.00–0.04] to 0.0 [0.00–0.97]; SUCRA probabilities of 10%). Therapies containing rifapentine (Rp1500HEZ, Rp900HEZ) and moxifloxacin (RMEZ, RHMZ) are effective regarding culture conversion, but statistical uncertainty on their safety profile exists. Conclusion: The WHO standard regimen remains an overall effective and safe alternative for DS-TB. For intensive phase treatments, drugs combinations with rifapentine and moxifloxacin seem to reduce treatment duration while maintaining efficacy.

5 September 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
JSJosiane M. Santos
Josiane M. Santos
MFMariana Millan Fachi
Mariana Millan Fachi
FBFrancisco Beraldi-Magalhaes
Francisco Beraldi-Magalhaes
BBBeatriz Böger
Beatriz Böger
AJAllan M. Junker
Allan M. Junker
RPRoberto Pontarolo
Roberto Pontarolo

20 December 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
FBFrancisco Beraldi-Magalhaes
Francisco Beraldi-Magalhaes
SPSuzanne L Parker
Suzanne L Parker
CSCristina Sancehs
Cristina Sancehs
LGLeandro Sousa Garcia
Leandro Sousa Garcia
BCBrenda Karoline Souza Carvalho
Brenda Karoline Souza Carvalho
JRJason Roberts
Jason Roberts
Background: Tuberculosis (TB) patients admitted to intensive care units (ICU) have high mortality rates. It is uncertain whether the pharmacokinetics of first-line TB drugs in ICU patients are different from outpatients. This study aims to compare the pharmacokinetics of oral ethambutol in TB patients in ICU versus TB outpatients and to determine whether contemporary dosing regimens achieve therapeutic exposures. Methods: A prospective population pharmacokinetic study of ethambutol was performed in Amazonas State, Brazil. Probability of target attainment was determined using AUC/MIC > 11.9 and Cmax/MIC > 0.48 values. Optimized dosing regimens were simulated at steady state. Results: Ten ICU patients and 20 outpatients were recruited. Ethambutol pharmacokinetics were best described using a two-compartment model with first-order oral absorption. Neither ICU patients nor outpatients consistently achieved optimal ethambutol exposures. The absorption rate for ethambutol was 2-times higher in ICU patients (p < 0.05). Mean bioavailability for ICU patients was >5-times higher than outpatients (p < 0.0001). Clearance and volume of distribution were 93% (p < 0.0001) and 53% (p = 0.002) lower in ICU patients, respectively. Conclusions: ICU patients displayed significantly different pharmacokinetics for an oral fixed-dose combination administration of ethambutol compared to outpatients, and neither patient group consistently achieved pre-defined therapeutic exposures.